- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04809350
Human Milk Fortification With Adjustable Versus Targeted Method (FAT)
Effect of Adjustable Versus Targeted Human Milk Fortification on Weight Gain in Preterm Infants With Birth Weight <1250 g: A Randomized Controlled Trial
Research question: Do preterm infants born <1250 g achieve better weight gain with targeted fortification compared with the adjustable fortification of human milk?
Hypothesis: Targeted fortification of human milk results in better weight gain in infants with birth weight <1250 gr when compared to the adjustable fortification.
Study design: Open-label, pragmatic, parallel randomized controlled trial in appropriate for gestational age infants with birth weight <1250 g.
Study Overview
Status
Conditions
Detailed Description
Human milk is the ideal diet for neonates. However, it does not provide enough energy, protein, and sodium to meet the nutritional requirements of very preterm infants. Postnatal growth failure is common despite the current use of human milk fortifiers. The main human milk fortification methods include:
- standard HM fortification (SF) which assumes an average composition of breast milk and adds fortifiers in a fixed dosage. It does not account for variations of nutrient content in human milk
Individualized human milk fortification which encompasses two methods:
- Adjustable HM fortification (AF): Protein supplementation is provided in addition to SF according to blood urea nitrogen (BUN) concentration which reflects the infant's metabolic response to protein intake. However, there are clinical scenarios in which the BUN levels are not a reliable marker of protein intake, such as acute kidney injury.
- Targeted HM fortification (TF): Based on routine analyses of HM that are used to adjust fortification to meet the recommended requirements for infants. It does not take into consideration that the requirements of infants may vary.
SF has frequently failed to achieve appropriate weight gain, while individualized (AF or TF) fortification seems to have better performance. However, the evidence to support one method over the other is lacking.
The objective of the study is to compare weekly average weight gain between preterm infants on AF versus TF.
Once the written consent is obtained, the infant will be randomized to AF or TF. The sequence code will be kept in sequential numbered sealed envelopes. Infants from multiple births will be included as 1 unit and randomized to the same arm of the study.
For patients allocated to the TF group, breast milk will be analyzed twice weekly for energy, protein, and sodium contents. The daily protein, fat, and sodium intakes will be then calculated and optimized to meet the recommended dietary reference intake (DRI) for preterm infants with birth weight <1250 g.
For patients allocated to the AF group, weekly BUN measurements will be performed. Based on BUN concentrations, the liquid protein will be added to achieve the targeted BUN level. Additional calories will be added using formula if growth is suboptimal or DRI is not met based on the assumed human milk content for protein and energy.
The intervention will last 4-8 weeks. For all patients, the day the first BUN concentration and milk analyses are done will be day 1 of intervention. The following measurements will be performed on days 7-8, 14-16, 21-23, and 28-30 of intervention: Weight (grams), length and head circumference (centimeters), BUN and sodium concentrations.
Data on maternal and neonatal characteristics will be collected from their electronic and physical charts.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Belal N Alshaikh, MD, MSc
- Phone Number: 4039561588
- Email: balshaik@ucalgary.ca
Study Contact Backup
- Name: Adriana Reyes Loredo, MD
- Email: adriana.reyesloredo@albertahealthservices.ca
Study Locations
-
-
Alberta
-
Calgary, Alberta, Canada, T2N2T9
- Recruiting
- Foothills Medical Centre
-
Contact:
- Belal Alshaikh, MD
-
Principal Investigator:
- Belal Alshaikh, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Infants with birth weight <1250 g born at Foothills Medical Centre.
- Appropriate for gestational age (AGA) (according to Fenton's Charts).
Exclusion Criteria:
- Abnormal Newborn Metabolic Screen
- Major congenital anomalies intervention.
- Patients who develop NEC prior to enrollment.
- Patients with confirmed congenital Toxoplasmosis, Syphilis, Rubella, Cytomegalovirus, Herpes simplex virus, Varicella and/or Zika (TORCH infections).
- Patients receiving systemic steroids.
- Patients with acute kidney injury (AKI).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Adjustable Human Milk Fortification
Human milk fortification based on blood urea levels
|
BUN and sodium concentrations will be measured every week in infants on full enteral feeds with fortified human milk. Liquid protein will be added based on serum urea. |
Experimental: Targeted Human Milk Fortification
Human milk fortification based on milk analysis
|
Human milk will be analyzed twice weekly. Before the day of analysis, each mother will store fresh milk pumped from 10:00 AM until 8:00 AM of the previous day in a refrigerator and bring it to the hospital. Protein, fat, and sodium supplementation will be added to the human milk to meet the recommended daily intakes. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Average weight gain in infants on Adjustable versus Targeted human milk fortification
Time Frame: Weekly for 8 weeks
|
Average weight gain measured as g/kg per day
|
Weekly for 8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Anthropometrics in infants on Adjustable versus Targeted human milk fortification
Time Frame: Weekly for 8 weeks
|
Measurement of head circumference and length in centimeters.
|
Weekly for 8 weeks
|
BUN concentration in infants on Adjustable versus Targeted human milk fortification
Time Frame: Weekly for 4 weeks
|
mmol/L
|
Weekly for 4 weeks
|
Incidence of extra uterine growth restriction
Time Frame: At 36 weeks CA
|
Defined as weight less than 10th percentile at 36 weeks corrected age (CA)
|
At 36 weeks CA
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Belal Alshaikh, MD, MSc, University of Calgary
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- REB20-2139
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Growth Failure
-
Northwell HealthRecruitingGrowth | Growth Disorders | Growth Failure | Growth Hormone TreatmentUnited States
-
Tufts UniversityHelen Keller International; Purdue University; Patan Academy of Health Sciences; Government of Nepal and other collaboratorsCompletedBirth Weight | Stunting | Birth Length | Linear Growth Failure | Height for Age
-
EMD SeronoCompletedGrowth Hormone Deficiency | Growth FailureGermany
-
IpsenCompletedGrowth Disorders | Insulin-Like Growth Factor-1 DeficiencyUnited States
-
Danone Specialized Nutrition IndonesiaLMU Klinikum; Hasanuddin University; RIKENActive, not recruitingGrowth FailureIndonesia
-
University of Texas Southwestern Medical CenterActive, not recruitingGrowth Disorders | Growth Failure | PrematurityUnited States
-
Soroka University Medical CenterWithdrawn
-
Columbia UniversityRecruitingGrowth Failure | Growth Retardation | Prematurity; Extreme | Infant Nutrition Disorders | Failure to Thrive in NewbornUnited States
-
Danone Specialized Nutrition (M) Sdn BhdUniversiti Putra MalaysiaRecruiting
Clinical Trials on Adjustable Human Milk Fortification
-
Loma Linda UniversityRecruitingPremature Birth | Postnatal Growth Restriction | Breastmilk CollectionUnited States
-
Columbia UniversityRecruitingGrowth Failure | Growth Retardation | Prematurity; Extreme | Infant Nutrition Disorders | Failure to Thrive in NewbornUnited States
-
The Hospital for Sick ChildrenRecruitingVery Low Birth Weight InfantCanada
-
McMaster Children's HospitalUnknownNeurodevelopment | Postnatal Growth DisorderCanada
-
MetroHealth Medical CenterTerminatedHuman Milk | Breast Milk | NeonateUnited States
-
McMaster Children's HospitalCompletedPostnatal Growth DisorderCanada
-
Children's National Research InstituteNot yet recruitingVery Low Birth Weight Infant | Very Preterm Maturity of InfantUnited States
-
The University of Texas Health Science Center at...Baylor College of Medicine; Columbia University; University of Oklahoma; University... and other collaboratorsCompletedCongenital Heart DefectUnited States
-
Rennes University HospitalCompleted
-
Augusta UniversityNeolac Inc dba Medolac LaboratoriesUnknownPremature Infant | Breast Milk ExpressionUnited States